+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2026-2032- Product Image
Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2026-2032- Product Image
Sale

Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989916
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cell Therapy Market is projected to reach USD 7.21 Billion in 2026. It is expected to continue growing at a CAGR of 12.59%, reaching USD 14.73 Billion by 2032.

Cell therapy is moving from a breakthrough modality into a core pillar of advanced healthcare, spanning CAR T-cell therapy, tumor-infiltrating lymphocyte therapy, hematopoietic stem cell transplantation, mesenchymal stromal cell applications, induced pluripotent stem cell platforms, and emerging allogeneic cell therapy programs. Since the first U.S. FDA approval of a CAR T-cell therapy in 2017, regulators have authorized multiple cellular medicines for hematologic malignancies, and the 2024 U.S. approval of the first TIL therapy for advanced melanoma further validated the clinical and therapeutic relevance of engineered and expanded living medicines.

The cell therapy market is being shaped by strong demand in oncology, rising investment in autoimmune and inflammatory disease programs, advances in cell therapy manufacturing, and the need for scalable, quality-controlled supply chains. For industry leaders, the most defensible opportunities are forming where clinical efficacy, durable patient response, manufacturing reliability, reimbursement readiness, and real-world evidence generation converge.

Transformative Shifts in the Cell Therapy Landscape

The cell therapy landscape is shifting from individualized, hospital-centered treatment pathways toward more industrialized platforms that can support broader patient access. Autologous CAR T-cell therapy remains a benchmark for clinical value in blood cancers, but long vein-to-vein timelines, complex logistics, and high production costs are accelerating development of allogeneic, in vivo, and automated manufacturing models.

Scientific progress is also widening the addressable disease base. Cell therapies are advancing beyond hematologic malignancies into solid tumors, autoimmune diseases, rare genetic disorders, regenerative medicine, and transplant-related indications. At the same time, regulators are emphasizing potency assays, comparability, long-term follow-up, and post-market safety surveillance, making evidence quality a central competitive differentiator.

Cumulative Impact of Artificial Intelligence on Cell Therapy

Artificial intelligence is becoming a cumulative force across the cell therapy value chain by improving target discovery, donor and patient stratification, process development, quality analytics, and clinical trial design. AI-enabled image analysis, multi-omics modeling, and machine learning applied to manufacturing data can help identify potency markers, predict batch variability, and support faster root-cause analysis when deviations occur.

The impact is especially important for cell therapy manufacturing, where living products are sensitive to starting material quality, culture conditions, and logistics. AI does not replace regulatory-grade validation, but it can strengthen process control, reduce failed batches, and support adaptive trial enrollment when integrated with compliant data governance, explainable models, cybersecurity controls, and human oversight.

Key Regional Insights for Cell Therapy

North America remains one of the most mature regions for cell therapy, led by the United States through FDA-approved CAR T-cell therapies, a deep biotechnology financing ecosystem, strong academic medical centers, and established specialty treatment networks. Canada is also advancing through hospital-based cell therapy programs, public research initiatives, and regenerative medicine collaborations, although manufacturing scale, payer coordination, and geographic access remain key priorities.

Europe benefits from the European Medicines Agency’s advanced therapy medicinal product framework and strong translational research clusters across Germany, France, Italy, Spain, and the United Kingdom. The European Union’s centralized regulatory pathway supports cross-border authorization, while country-level health technology assessment, hospital exemption practices, national pricing systems, and reimbursement processes continue to shape launch sequencing and patient access.

Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN markets invest in regenerative medicine, oncology innovation, clinical trial capacity, and domestic manufacturing capabilities. China has built a large clinical development base for CAR T-cell therapy, Japan operates a regenerative medicine regulatory framework designed to support conditional and time-limited access, and South Korea and Australia are strengthening advanced therapy infrastructure through biomanufacturing, translational research, and internationally credible clinical trial systems.

Latin America, the Middle East, and Africa are at earlier but increasingly strategic stages of adoption. Brazil and Mexico are regional anchors for clinical research, transplant capabilities, and specialty oncology care in Latin America. GCC countries are investing in medical hubs, genomics, precision medicine infrastructure, and specialized hospitals, while African markets are gradually building capacity through oncology centers, hematopoietic stem cell transplant programs, public health partnerships, and international collaborations focused on equitable access.

Key Group Insights Across Global Cell Therapy Markets

The European Union and G7 economies are central to cell therapy commercialization because they combine advanced regulatory systems, high healthcare spending, robust intellectual property protection, established pharmacovigilance practices, and mature clinical trial networks. These markets often set global expectations for quality, comparability, long-term safety follow-up, reimbursement evidence, and health economic value demonstration for advanced therapy medicinal products.

BRICS countries are increasingly important to cell therapy development due to large patient populations, rising biomanufacturing capacity, expanding oncology infrastructure, and government support for biotechnology self-reliance. China and India are particularly influential within BRICS, with China leading in cell therapy clinical activity and India expanding cost-efficient bioprocessing, hospital networks, domestic innovation, and access-oriented treatment models.

ASEAN offers a diverse growth corridor where Singapore acts as a biomedical hub and Thailand, Malaysia, Indonesia, Vietnam, and the Philippines continue building capacity in specialty care, clinical research, and regenerative medicine services. GCC markets are investing in high-acuity medical infrastructure, genomics-led healthcare, and medical tourism capabilities, while NATO members overlap significantly with advanced North American and European research ecosystems that support resilient supply chains, clinical collaboration, quality standards, and regulatory alignment.

Key Country Insights in Cell Therapy

The United States leads the global cell therapy market through FDA approvals, academic medical centers, clinical trial activity, specialized treatment networks, and advanced manufacturing capacity. Canada complements this ecosystem with strong public research institutions, cell therapy networks, and hospital-based programs, while Mexico is gaining relevance through specialty care, clinical capabilities, and manufacturing-adjacent opportunities in North America. Brazil is Latin America’s most important cell therapy hub due to its research hospitals, transplant expertise, public health system experience, and expanding oncology infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major centers for advanced therapy research, clinical adoption, regulatory engagement, and reimbursement evaluation. Germany and France provide strong biomanufacturing and hospital networks, the United Kingdom remains influential through innovation pathways, academic excellence, and early-access mechanisms, while Italy and Spain contribute significant transplant, oncology, and hospital-based advanced therapy expertise. Russia maintains scientific capabilities in cell-based research and transplant medicine but faces greater international collaboration, procurement, and supply chain constraints.

In Asia-Pacific, China has become a major center for CAR T-cell therapy development and clinical trials, supported by large patient access, hospital networks, and domestic innovation policies, while India is expanding affordable biotechnology platforms, stem cell research governance, and hospital-based advanced care. Japan’s regenerative medicine framework and established pharmaceutical sector support translation, South Korea is investing in biomanufacturing, cell therapy startups, and regulatory modernization, and Australia provides a strong clinical trial environment, translational research networks, and high regulatory credibility.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturability as early as clinical design. Programs with clear potency assays, scalable closed-system manufacturing, robust chain-of-identity and chain-of-custody controls, validated cryopreservation strategies, and standardized release testing are better positioned for regulatory review, commercialization, and reliable patient delivery.

Organizations should also build reimbursement evidence from the start by linking clinical endpoints to durability, quality of life, hospital utilization, safety management, and total cost of care. Partnerships with academic centers, contract manufacturers, data platforms, logistics specialists, and payer stakeholders can accelerate development while reducing execution risk in a market where scientific success must be matched by operational excellence.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with established standards for market intelligence. Inputs include regulatory agency disclosures, clinical trial registries, peer-reviewed literature, public health authority updates, patent and product approval information, reimbursement policy documents, and validated industry sources covering cell therapy, CAR T-cell therapy, stem cell therapy, regenerative medicine, and advanced therapy medicinal products.

The analysis emphasizes triangulation across scientific, regulatory, commercial, manufacturing, and regional indicators. Market interpretations are derived from observable evidence such as therapy approvals, clinical development activity, manufacturing investments, reimbursement pathways, treatment infrastructure, safety requirements, and regional policy frameworks rather than unsupported claims.

Conclusion

Cell therapy is entering a decisive phase in which clinical validation, manufacturing scale, AI-enabled process intelligence, and reimbursement evidence will determine market leadership. The sector’s strongest momentum remains in oncology, but autoimmune disease, regenerative medicine, solid tumor research, and allogeneic platforms are widening the long-term opportunity for advanced cellular medicines.

Organizations that combine scientific differentiation with operational discipline will be best positioned to capture value. As global regions build capacity and regulators refine expectations, the next phase of the cell therapy market will reward stakeholders that can deliver safe, effective, accessible, quality-controlled, and economically sustainable living medicines.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cell Therapy Market, by Type
7.1. Non-stem Cells
7.1.1. CAR-T Cells
7.1.2. Dendritic Cells
7.1.3. NK Cells
7.2. Stem Cells
7.2.1. Embryonic Stem Cells
7.2.2. Hematopoietic Stem Cell
7.2.3. Mesenchymal Stem Cell
8. Cell Therapy Market, by Therapy Type
8.1. Allogenic
8.2. Autologous
9. Cell Therapy Market, by Mode of Administration
9.1. Intramuscular
9.2. Intratumoral
9.3. Intravenous
10. Cell Therapy Market, by Application
10.1. Autoimmune Disorders
10.1.1. Multiple Sclerosis
10.1.2. Rheumatoid Arthritis
10.2. Cancer Treatment
10.2.1. Hematologic Malignancies
10.2.2. Solid Tumors
10.3. Infectious Diseases
10.3.1. Bacterial Infections
10.3.2. Viral Infections
10.4. Regenerative Medicine
11. Cell Therapy Market, by End User
11.1. Academic & Research Institutes
11.2. Clinics
11.3. Commercial Laboratories
11.4. Hospitals
12. Asia-Pacific Cell Therapy Market
13. Europe Cell Therapy Market
14. North America Cell Therapy Market
15. Latin America Cell Therapy Market
16. Africa Cell Therapy Market
17. Middle East Cell Therapy Market
18. NATO Cell Therapy Market
19. G7 Cell Therapy Market
20. European Union Cell Therapy Market
21. BRICS Cell Therapy Market
22. ASEAN Cell Therapy Market
23. GCC Cell Therapy Market
24. United States Cell Therapy Market
25. China Cell Therapy Market
26. Germany Cell Therapy Market
27. Japan Cell Therapy Market
28. India Cell Therapy Market
29. United Kingdom Cell Therapy Market
30. France Cell Therapy Market
31. Canada Cell Therapy Market
32. Italy Cell Therapy Market
33. Australia Cell Therapy Market
34. South Korea Cell Therapy Market
35. Brazil Cell Therapy Market
36. Mexico Cell Therapy Market
37. Russia Cell Therapy Market
38. Spain Cell Therapy Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Allogene Therapeutics, Inc.
40.2. Anterogen Co., Ltd.
40.3. Astellas Pharma Inc.
40.4. Athersys, Inc.
40.5. BioNTech SE
40.6. Bristol-Myers Squibb Company
40.7. Castle Creek Biosciences, Inc.
40.8. Catalent, Inc.
40.9. FUJIFILM Holdings Corporation
40.10. Gilead Sciences, Inc.
40.11. JCR Pharmaceuticals Co., Ltd.
40.12. Kolon TissueGene, Inc.
40.13. Lonza Group Ltd.
40.14. Lovance Biotherapeutics, Inc.
40.15. Medipost Co., Ltd.
40.16. Mesoblast Ltd.
40.17. Novartis AG
40.18. Pfizer Inc.
40.19. Sartorius AG
40.20. Stemedica Cell Technologies, Inc.
40.21. Stempeutics Research Pvt. Ltd.
40.22. Takeda Pharmaceutical Company Limited
40.23. TegoScience
40.24. Thermo Fisher Scientific, Inc.
40.25. Vericel Corporation
List of Figures
FIGURE 1. GLOBAL CELL THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CELL THERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CELL THERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CELL THERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL CELL THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CHINA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. GERMANY CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. JAPAN CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. INDIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CANADA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. AUSTRALIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. BRAZIL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. MEXICO CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL CELL THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NON-STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NON-STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NON-STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CAR-T CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CAR-T CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CAR-T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DENDRITIC CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DENDRITIC CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DENDRITIC CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NK CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NK CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NK CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ALLOGENIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ALLOGENIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ALLOGENIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL INTRATUMORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL INTRATUMORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL INTRATUMORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. EUROPE CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 108. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 109. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 114. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 115. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. AFRICA CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 140. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 141. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 142. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 143. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 145. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 146. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 147. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 148. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. NATO CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. NATO CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 162. NATO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 163. NATO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 164. NATO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 165. NATO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. NATO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 167. NATO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 168. NATO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 169. NATO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 170. NATO CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. G7 CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 172. G7 CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 173. G7 CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 174. G7 CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 175. G7 CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 176. G7 CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. G7 CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 178. G7 CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 179. G7 CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 180. G7 CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 181. G7 CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. BRICS CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 194. BRICS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 195. BRICS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 196. BRICS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 197. BRICS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 198. BRICS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. BRICS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 200. BRICS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 201. BRICS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 202. BRICS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 203. BRICS CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. ASEAN CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 205. ASEAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 206. ASEAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 207. ASEAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 208. ASEAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 209. ASEAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 210. ASEAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 211. ASEAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 212. ASEAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 213. ASEAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 214. ASEAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. GCC CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. GCC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 217. GCC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 218. GCC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 219. GCC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 220. GCC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. GCC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 222. GCC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 223. GCC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 224. GCC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 225. GCC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. CHINA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 238. CHINA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 239. CHINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 240. CHINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 241. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 242. CHINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 244. CHINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 245. CHINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 246. CHINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 247. CHINA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 248. GERMANY CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 249. GERMANY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 250. GERMANY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 251. GERMANY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 252. GERMANY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 253. GERMANY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. GERMANY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 255. GERMANY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 256. GERMANY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 257. GERMANY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 258. GERMANY CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 259. JAPAN CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. JAPAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 261. JAPAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 262. JAPAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 263. JAPAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 264. JAPAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 265. JAPAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 266. JAPAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 267. JAPAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 268. JAPAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 269. JAPAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 270. INDIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 271. INDIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 272. INDIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 273. INDIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 274. INDIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 275. INDIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 276. INDIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 277. INDIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 278. INDIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 279. INDIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 280. INDIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 292. FRANCE CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 293. FRANCE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 294. FRANCE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 295. FRANCE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 296. FRANCE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 297. FRANCE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 298. FRANCE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 299. FRANCE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 300. FRANCE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 301. FRANCE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 302. FRANCE CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 303. CANADA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 304. CANADA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 305. CANADA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 306. CANADA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 307. CANADA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 308. CANADA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 309. CANADA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 310. CANADA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 311. CANADA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 312. CANADA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 313. CANADA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 314. ITALY CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 315. ITALY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 316. ITALY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 317. ITALY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 318. ITALY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 319. ITALY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 320. ITALY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 321. ITALY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 322. ITALY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 323. ITALY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 324. ITALY CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 325. AUSTRALIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 326. AUSTRALIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 327. AUSTRALIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 328. AUSTRALIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 329. AUSTRALIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 330. AUSTRALIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 331. AUSTRALIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 332. AUSTRALIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 333. AUSTRALIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 334. AUSTRALIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 335. AUSTRALIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 336. SOUTH KOREA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 337. SOUTH KOREA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 338. SOUTH KOREA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 339. SOUTH KOREA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 340. SOUTH KOREA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 341. SOUTH KOREA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 342. SOUTH KOREA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 343. SOUTH KOREA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 344. SOUTH KOREA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 345. SOUTH KOREA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 346. SOUTH KOREA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 347. BRAZIL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 348. BRAZIL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 349. BRAZIL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 350. BRAZIL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 351. BRAZIL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 352. BRAZIL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 353. BRAZIL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 354. BRAZIL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 355. BRAZIL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 356. BRAZIL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 357. BRAZIL CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 358. MEXICO CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 359. MEXICO CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 360. MEXICO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 361. MEXICO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 362. MEXICO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 363. MEXICO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 364. MEXICO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 365. MEXICO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 366. MEXICO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 367. MEXICO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 368. MEXICO CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 369. RUSSIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 370. RUSSIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 371. RUSSIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 372. RUSSIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 373. RUSSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 374. RUSSIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 375. RUSSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 376. RUSSIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
TABLE 377. RUSSIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
TABLE 378. RUSSIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 379. RUSSIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 380. SPAIN CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 381. SPAIN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 382. SPAIN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
TABLE 383. SPAIN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
TABLE 384. SPAIN CELL THERAPY

Companies Mentioned

The companies featured in this Cell Therapy market report include:
  • Allogene Therapeutics, Inc.
  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Castle Creek Biosciences, Inc.
  • Catalent, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Lonza Group Ltd.
  • Lovance Biotherapeutics, Inc.
  • Medipost Co., Ltd.
  • Mesoblast Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sartorius AG
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • TegoScience
  • Thermo Fisher Scientific, Inc.
  • Vericel Corporation

Table Information

Report AttributeDetails
No. of Pages190
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.21 Billion
Forecasted Market Value ( USD ) by 2032 $ 14.73 Billion
Compound Annual Growth Rate12.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Allogeneic Cell Therapy Market - Global Forecast 2026-2032 - Product Image

Allogeneic Cell Therapy Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Autologous Cell Therapies Market - Global Forecast 2026-2032 - Product Image

Autologous Cell Therapies Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Allogeneic Cell Therapy - Global Strategic Business Report - Product Image

Allogeneic Cell Therapy - Global Strategic Business Report

  • Report
  • 275 Pages
  • Global
From
Cell Therapy Market Report and Forecast 2025-2034 - Product Image

Cell Therapy Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Cell Therapy Market Size, Share, Trends and Forecast by Cell Type, Therapy Type, Therapeutic Area, End User, and Region, 2026-2034 - Product Image

Cell Therapy Market Size, Share, Trends and Forecast by Cell Type, Therapy Type, Therapeutic Area, End User, and Region, 2026-2034

  • Report
  • 141 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.